Subscribe
shutterstock_399778786_paul_brady_photography
Paul Brady Photography / Shutterstock.com
7 December 2020AmericasSarah Morgan

Number of pay-for-delay deals remains low, says FTC

The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission (FTC).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
EC fines Teva €60.5m over pay-for-delay deal
27 November 2020   The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.
Big Pharma
‘Considerable increase’ in pay-for-delay settlements: FTC report
24 May 2019   The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.
Americas
Tris blocks Actavis’ ADHD generic
10 December 2020   New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
EC fines Teva €60.5m over pay-for-delay deal
27 November 2020   The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.
Big Pharma
‘Considerable increase’ in pay-for-delay settlements: FTC report
24 May 2019   The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.
Americas
Tris blocks Actavis’ ADHD generic
10 December 2020   New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

More on this story

Big Pharma
EC fines Teva €60.5m over pay-for-delay deal
27 November 2020   The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.
Big Pharma
‘Considerable increase’ in pay-for-delay settlements: FTC report
24 May 2019   The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.
Americas
Tris blocks Actavis’ ADHD generic
10 December 2020   New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?